Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer

DIRK RADES, LISA MANIG, STEFAN JANSSEN and STEVEN E. SCHILD
Anticancer Research March 2017, 37 (3) 1481-1484;
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rades.dirk@gmx.net
LISA MANIG
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFAN JANSSEN
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
2Private Practice of Radiation Oncology, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVEN E. SCHILD
3Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To create a survival score for patients with metastatic bladder cancer. Patients and Methods: In 46 irradiated patients, six characteristics were evaluated for their association with survival: Age, gender, Karnofsky performance scale, initial stage (American Joint Committee on Cancer), number of metastatic sites, and interval between bladder cancer diagnosis and palliative radiotherapy. Characteristics showing a trend (p<0.15) were incorporated into the score. Six-month survival rates were divided by 10. Patients' scores were derived by totaling the scores of these characteristics. Results: Performance scale (p=0.14), stage (p=0.055) and number of metastatic sites (p=0.10) showed a trend for association with survival. Patients' scores were 6, 7, 8, 10 or 12 points, with corresponding 6-month survival rates of 20%, 0%, 0%, 46% and 45% (p=0.038). Two groups were created, with 6-8 and with 10-12 points, with 6-month survival rates of 9% and 46% (p=0.002), respectively. Conclusion: A new survival score was developed. Patients with 6-8 points should receive less aggressive treatments for metastatic bladder cancer. Those with 10-12 points may receive more intensive approaches.

  • Metastatic bladder cancer
  • radiotherapy
  • palliation
  • personalized treatment
  • survival score

Patients who present with metastatic bladder cancer generally have a poor prognosis, surviving only very few months (1). However, some patients may live considerably longer. If a patient is able to withstand palliative chemotherapy, their remaining lifetime may be extended with systemic treatments. Patients who are unable to tolerate chemotherapy are often referred to a radiation oncologist for palliative irradiation aiming to relieve or prevent debilitating symptoms (2, 3). In such palliative situations personalized treatment concepts account for the patient's preferences and needs, as well as their expected survival time.

Patients with a very short remaining lifespan should ideally not receive too intensive or time-consuming treatment programs. In contrast, patients with a much more favorable prognosis could benefit from more intensive approaches with higher total radiation doses. This concept was reported for radiotherapy of metastatic disease from other primary tumor types (4, 5). Tailoring a treatment program to an individual patient receiving palliative radiotherapy of metastatic bladder cancer during clinical routine would be easier if a simple tool was available allowing an estimation of such a patient's survival time. This study was conducted to develop such an instrument, specifically designed for patients irradiated for metastatic bladder cancer. Since a previous study suggested that the prognosis of these patients may be influenced by the radiation dose, only patients who received an equivalent dose in 2 Gy fractions (EQD2) of more than 30 Gy (6) were included.

Patients and Methods

In 46 patients who received palliative radiotherapy with an EQD2 greater than 30 Gy for metastatic bladder cancer, six characteristics were retrospectively evaluated with respect to their impact on survival. The six characteristics (Table I) were age at palliative radiotherapy (≤70 vs. >70 years, median=70 years), gender, Karnofsky performance scale (KPS ≤60% vs. >60%, median KPS=70%), initial tumor stage according to the American Joint Committee on Cancer (7) (AJCC stage ≤3 vs. 4, median=3), number of organ sites involved by metastatic disease (1 vs. ≥2 sites, median=1), and the interval between the first diagnosis of bladder cancer and palliative radiotherapy (≤12 vs. >12 months, median=13 months).

For the survival analyses, the Kaplan–Meier method was used supplemented by the log-rank test (8). Those characteristics having at least a trend towards an impact on survival (p<0.15) were incorporated into the survival score. For this score, the 6-month survival rates of the corresponding characteristics were taken and divided by 10. The prognostic score for a single patient was derived by adding the scores of all characteristics that showed a trend in the survival analysis.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Distribution of the six evaluated characteristics.

Results

On survival analysis, KPS (p=0.14), initial AJCC stage (p=0.055) and number of sites involved by metastatic disease (p=0.10) showed a trend towards an association with survival (Table II) and were, therefore, incorporated into the scoring tool.

The scores in relation to these characteristics are presented in Table III. Scores for single patients were 6, 7, 8, 10 or 12 points. The corresponding 6-month survival rates were 20%, 0%, 0%, 46% and 45%, respectively (p=0.038; Figure 1). Based on these survival rates, two prognostic groups were created, with 6-8 points and with 10-12 points. The corresponding 6-month survival rates of these two groups were 9% and 46%, respectively (p=0.002, Figure 2).

Discussion

About every fourth patient with bladder cancer develops distant metastases during the course of their disease (9). Most of these patients have a poor prognosis that urgently requires improvement. On one hand, this may be achieved with chemotherapy programs or novel targeted therapies, such as agents that have an effect on the phosphatidylinositol-3-kinase–protein kinase B pathway, and other modern approaches of systemic treatments (10-13). Personalized medicine is another promising approach to improving the prognosis of patients with metastatic cancer, including those with metastases from bladder cancer. To optimally utilize personalized anticancer treatment, the treating physicians have to be able to estimate an individual patient's remaining lifespan as precisely as possible. To achieve this goal, precise knowledge of predictors of survival is very helpful. Moreover, a simple scoring tool that can easily be used in clinical routine is desirable to allow a quick and appropriate selection of an optimal treatment approach for an individual patient.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Three- and 6-month survival rates of the evaluated characteristics.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Characteristics incorporated in the score and corresponding scoring points.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The 6-month survival rates obtained from the Kaplan–Meier analysis in relation to the scores calculated for each single patient.

In the current study, such a tool was created for patients who received palliative radiotherapy for metastatic bladder cancer. Based on three potential prognostic factors, namely KPS, initial AJCC stage and the number of sites involved by metastatic disease, we derived two prognostic groups with significantly different 6-month survival rates. Patients with a total score of 6-8 had a 6-month survival rate of only 9%. Therefore, these patients can be considered candidates for a short and less intensive radiotherapy program. Several studies of palliative radiotherapy for metastases from solid tumors including bladder cancer have shown that a significant relief of symptoms can be achieved also with short radiotherapy programs that last only one day or one week. This has for example been demonstrated already for irradiation of painful bone metastases, metastatic spinal cord compression and brain metastases (2, 3, 14-17).

In the group of patients who achieved a score of 10-12 in the present study the 6-month survival rate was 46%, i.e. much better than in the groups with 6-8 points. Therefore, these patients may be considered for longer-lasting radiotherapy programs including higher total doses greater than 30 Gy. Previous studies of palliative radiotherapy for metastatic spinal cord compression and brain metastases have shown that patients with a better survival prognosis benefit from higher doses in terms of improved local control and survival (4, 5). When following these recommendations, one should be aware of the limitations of the present study, namely its retrospective nature and the relatively small number of patients. Retrospective studies bear a certain risk of including hidden biases. In order to reduce the risk of bias, only patients receiving an EQD2 of more than 30 Gy were included in this study (6). Ideally, the results would be confirmed in a prospective trial. However, since patients with bladder cancer account for only about 2% of all patients with cancer, such a prospective trial with an adequate statistical power cannot be expected soon (18).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier curves of the overall survival of the two prognostic groups: with 6-8 points and 10-12 points (p-value obtained from log-rank test).

In summary, a new survival score was developed for patients receiving palliative radiotherapy for metastatic bladder cancer. Patients who achieve 6-8 points should receive less burdensome and less time-consuming treatments. In patients achieving 10-12 points, more intensive approaches may result in better local control and survival.

Footnotes

  • This article is freely accessible online.

  • Conflicts of Interest

    On behalf of all Authors, the corresponding Author states that there is no conflict of interest related to this study.

  • Received January 6, 2017.
  • Revision received February 10, 2017.
  • Accepted February 13, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Guancial EA,
    2. Roussel B,
    3. Bergsma DP,
    4. Bylund KC,
    5. Sahasrabudhe D,
    6. Messing E,
    7. Mohile SG,
    8. Fung C
    : Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging 10: 939-949, 2015.
    OpenUrlPubMed
  2. ↵
    1. Rades D,
    2. Walz J,
    3. Schild SE,
    4. Veninga T,
    5. Dunst J
    : Do bladder cancer patients with metastatic spinal cord compression benefit from radiotherapy alone? Urology 69: 1081-1085, 2007.
    OpenUrlPubMed
  3. ↵
    1. Rades D,
    2. Meyners T,
    3. Veninga T,
    4. Stalpers LJA,
    5. Schild SE
    : Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder. Int J Radiation Oncology Biol Phys 78: 404-408, 2010.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Rades D,
    2. Panzner A,
    3. Rudat V,
    4. Karstens JH,
    5. Schild SE
    : Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. Strahlenther Onkol 187: 729-735, 2011.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Rades D,
    2. Panzner A,
    3. Dziggel L,
    4. Haatanen T,
    5. Lohynska R,
    6. Schild SE
    : Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis, Cancer 118: 3853-3859, 2012.
    OpenUrl
  6. ↵
    1. Manig L,
    2. Käsmann L,
    3. Janssen S,
    4. Rades D
    : Predicting survival after irradiation of metastases from transitional carcinoma of the bladder. Anticancer Res 36: 6663-6665, 2016.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Edge SB,
    2. Byrd DR,
    3. Compton CC,
    4. Fritz AG,
    5. Greene FL,
    6. Trotti A
    (eds.): AJCC Cancer Staging Manual (7th edition). New York, NY, Springer, 2010.
  8. ↵
    1. Kaplan E,
    2. Meier P
    : Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
    OpenUrlCrossRef
  9. ↵
    1. Goldman SM,
    2. Fajardo AA,
    3. Naraval RC,
    4. Madewall JE
    : Metastatic transitional cell carcinoma from the bladder: Radiographic manifestations. Am J Roentgenol 132: 419-425, 1979.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kilari D,
    2. Iczkowski KA,
    3. Pandya C,
    4. Robin AJ,
    5. Messing EM,
    6. Guancial E,
    7. Kim ES
    : Copper transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients. Anticancer Res 36: 495-501, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Jana BR,
    2. Zhou Y
    : Novel molecular targets for the therapy of urothelial cancer. Anticancer Res 35: 4557-4567, 2015.
    OpenUrlAbstract/FREE Full Text
    1. Lea MA,
    2. Guzman Y,
    3. Desbordes C
    : Inhibition of growth by combined treatment with inhibitors of lactate dehydrogenase and either phenformin or inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3. Anticancer Res 36: 1479-1488, 2016.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Nakagawa YU,
    2. Nagaya H,
    3. Miyata T,
    4. Wada Y,
    5. Oyama T,
    6. Gotoh A
    : Piperazine-based alpha-1 AR blocker, naftopidil, selectively suppresses malignant human bladder cells via induction of apoptosis. Anticancer Res 36: 1563-1570, 2016.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Rades D,
    2. Stalpers LJA,
    3. Veninga T,
    4. Schulte R,
    5. Hoskin PJ,
    6. Obralic N,
    7. Bajrovic A,
    8. Rudat V,
    9. Schwarz R,
    10. Hulshof MC,
    11. Poortmans P,
    12. Schild SE
    : Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 23: 3366-3375, 2005.
    OpenUrlAbstract/FREE Full Text
    1. Rades D,
    2. Šegedin B,
    3. Conde-Moreno AJ,
    4. Garcia R,
    5. Perpar A,
    6. Metz M,
    7. Badakhshi H,
    8. Schreiber A,
    9. Nitsche M,
    10. Hipp P,
    11. Schulze W,
    12. Adamietz IA,
    13. Norkus D,
    14. Rudat V,
    15. Cacicedo J,
    16. Schild SE
    : Radiotherapy with 4 Gy × 5 versus 3 Gy × 10 for metastatic epidural spinal cord compression: Final results of the SCORE-2 trial (ARO 2009/01). J Clin Oncol 34: 597-602, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Lutz S,
    2. Berk L,
    3. Chang E,
    4. Chow E,
    5. Hahn C,
    6. Hoskin P,
    7. Howell D,
    8. Konski A,
    9. Kachnic L,
    10. Lo S,
    11. Sahgal A,
    12. Silverman L,
    13. von Gunten C,
    14. Mendel E,
    15. Vassil A,
    16. Bruner DW,
    17. Hartsell W,
    18. American Society for Radiation Oncology (ASTRO)
    . Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79: 965-976, 2011.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tsao MN,
    2. Rades D,
    3. Wirth A,
    4. Lo SS,
    5. Danielson BL,
    6. Gaspar LE,
    7. Sperduto PW,
    8. Vogelbaum MA,
    9. Radawski JD,
    10. Wang JZ,
    11. Gillin MT,
    12. Mohideen N,
    13. Hahn CA,
    14. Chang EL
    : Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2: 210-25, 2012.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Jemal A,
    2. Siegel R,
    3. Ward E,
    4. Murray T,
    5. Xu J,
    6. Smigal C,
    7. Thun M
    : Cancer statistics, 2006. Cancer J Clinic 56: 106-130, 2006.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (3)
Anticancer Research
Vol. 37, Issue 3
March 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer
DIRK RADES, LISA MANIG, STEFAN JANSSEN, STEVEN E. SCHILD
Anticancer Research Mar 2017, 37 (3) 1481-1484;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer
DIRK RADES, LISA MANIG, STEFAN JANSSEN, STEVEN E. SCHILD
Anticancer Research Mar 2017, 37 (3) 1481-1484;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases
  • Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder
  • Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder
  • Patient-reported Symptom Burden, Rate of Completion of Palliative Radiotherapy and 30-day Mortality in Two Groups of Cancer Patients Managed With or Without Additional Care by a Multidisciplinary Palliative Care Team
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Metastatic bladder cancer
  • radiotherapy
  • palliation
  • personalized treatment
  • Survival score
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire